USP39 and plasma cell myeloma: To investigate the effects of targeting USP39 on the response of multiple myeloma (MM) cells to bortezomib (BTZ), we performed experiments utilizing both BTZ-sensitive (U266) and BTZ-resistant (U266R) MM cell lines, with the latter previously developed in our laboratory (Fig. 5).